The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 17, Pages 4263
Publisher
MDPI AG
Online
2019-08-30
DOI
10.3390/ijms20174263
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
- (2019) Jean-Christophe Pignon et al. CLINICAL CANCER RESEARCH
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
- (2019) Solène-Florence Kammerer-Jacquet et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?
- (2019) Alessandra Raimondi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis
- (2018) Raffaele Ratta et al. Clinical Genitourinary Cancer
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
- (2018) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
- (2018) Francesco Soria et al. WORLD JOURNAL OF UROLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- (2018) Stéphane Champiat et al. Nature Reviews Clinical Oncology
- iRECIST: A clarification of tumour response assessment in the immunotherapy era
- (2017) Charles Ferté et al. EUROPEAN JOURNAL OF CANCER
- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined disease progression in clinical trials
- (2017) Dickran Kazandjian et al. SEMINARS IN ONCOLOGY
- Multimodal treatment of advanced renal cancer in 2017
- (2017) Alessia Mennitto et al. Expert Review of Clinical Pharmacology
- Treatment Beyond Progression With Immune Checkpoint Inhibitors—Known Unknowns
- (2017) Gideon M. Blumenthal et al. JAMA Oncology
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Cellular immunotherapy for malignant gliomas
- (2016) Yi Lin et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma
- (2016) Alberto Farolfi et al. Expert Opinion on Drug Metabolism & Toxicology
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cancer
- (2016) Umberto Capitanio et al. LANCET
- Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
- (2016) Maria I. Carlo et al. Nature Reviews Urology
- Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
- (2016) Saby George et al. JAMA Oncology
- Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
- (2016) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment
- (2015) Mizuki Nishino et al. EUROPEAN JOURNAL OF RADIOLOGY
- A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer
- (2015) Laurence Albiges et al. EUROPEAN UROLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma
- (2015) G. de Velasco et al. Cancer Immunology Research
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
- (2014) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing oncologic benefit in clinical trials of immunotherapy agents
- (2010) R. K. Hales et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- New Response Criteria Proposed for Immunotherapies
- (2008) Rabiya S. Tuma JNCI-Journal of the National Cancer Institute
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started